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Abstract
The blood-brain barrier (BBB) is a highly selective semi-permeable membrane 
that separates the cerebral blood circulation from the brain and extracellular fluid 
in the central nervous system (CNS). The BBB is composed of endothelial cells, 
astrocyte end-feet and pericytes embedded in the capillary basement membrane. 
This system allows the passage of water, some gases and lipid-soluble molecules by 
passive diffusion, as well as, selective molecules such as glucose and amino acids. 
This review discusses pharmacodynamic concepts and methods that allow drugs to 
penetrate the BBB structure and enter the CNS and spinal nervous systems (SNS).
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1. Introduction
The blood-brain barrier (BBB) was discovered over 100 years ago by Paul 
Ehrlich during his studies on the brain [1]. Ehrlich’s early observations that water 
soluble dyes stained all organs of animals except for their brains and components 
of the central nervous system (CNS) was the key to our present day understanding 
of the BBB system. Subsequently, other researchers observed that dyes injected into 
the blood stream did not enter the brain hence a barrier existed between the two 
compartments [1].
The BBB differs from normal membranes in that it possesses tight junctions 
between an endothelial cell/astrocyte wall with no pores to allow for transport 
unless materials are lipophilic, water, and/or an actively transported. The BBB is 
also lipophilic, free of aqueous electrolytes and highly electrical resistant. However, 
the BBB compartment can be traversed by lipophilic substances through passive 
diffusion, while other molecules that are substrates for transferases cross by direct 
transport [1, 2].
The BBB prevents most systemic therapies from penetrating the brain; however, 
when cancer cells do penetrate the BBB from a peripheral origin, they generate 
neo-vascularization or cancer associated “vascular mimicry” structures (new 
blood vessels associated with tumor-generated penetrate breaks in the BBB) which 
can connect intracranial metastatic cancer cell colonies with the cerebral blood 
circulation [3]. If undesirable or toxic materials pass through the BBB into the CNS, 
a protective mechanism—the P-glycoprotein (P-gP) transfer system will transport 
toxic materials out of the CNS [4].
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Thus, developing new drugs that can exploit the cancer associated CNS “neo-
angiogenic” vascularization that are not substrates for the P-gP system is of major 
interest and would be very useful in managing CNS and SNS malignancies.
Figure 1 shows a simplified diagram describing the BBB in relation to the brain 
(CNS) or spinal nervous system (SNS), the cerebral circulation and tumors growing 
in the CNS or SNS (Figure 2).
2. Extravascular transport of cancer cells into the CNS
Not all cancer cells infiltrate the CNS or SNS by breaching the BBB. A recent 
report by Yao et al. describes how acute lymphocytic leukemia (ALL) cells possess 
a6 integrin receptors that bind to laminin, a glycoprotein molecule that covers the 
surfaces of the meninges, its nerve sheaths and blood vessels [6]. Tiny blood vessels 
pass directly from the bone marrow through the vertebrae to the meninges tissue 
that line the spinal cord, brain and the cerebral spinal fluid (CSF) circulation. ALL 
cells can attach to the outside of blood vessels and nerves in the bone marrow and 
migrate over the scaffolding proteins. Thus, ALL cells can slide into the CNS and 
Figure 2. 
Describes breaks in the BBB and neoangiogenesis that can be initiated by both metastatic and primary cancers 
in the CNS, allowing RBCs with drugs to cross the BBB and penetrate the CNS and tumor masses (modified 
from Ref. [5]).
Figure 1. 
Depicts three modes of drug transport to primary and secondary brain cancer tumors—direct passive 
permeability, active transport/transfer, and transport in association with RBCs (modified from Ref. [5]).
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SNS via the scaffolding of the cerebral vascular circulation [6]. Other types of 
cancer may be able to do the same.
The next step is to design new agents to block the a6 integrin receptor [6].
3.  Principles for selecting a drug for brain and spinal nervous  
systems—primary and secondary
Most therapy regimens for CNS and SNS cancers involve empirical protocols [7]. 
However, with the advent of tumor targeted and gene mutation designed immuno-
therapies, there are more selective therapeutic approaches to the management of 
cancers [8].
However, if a tumor lacks a specific tumor target antigen, genetic mutation 
or receptor glycoprotein, then a more individualized (personalized) approach is 
possible. Through in vitro sensitivity studies, cytotoxicity parameters (IC50) vs. 
selected drugs can be identified for each individual tumor [9]. Obtaining tumor 
tissue for tumor molecular profiling can now be easily accomplished using liquid 
biopsy techniques and stem cell cultures [9, 13].
In addition, since drugs penetrate the tumors in the CNS and SNS by lipo-
philic and/or selective transport mechanism(s), the partition coefficient, P 
value, is also helpful in appreciating whether a drug has a chance of penetrating 
the lipid rich BBB membrane or if a more selective transportation system is 
required.
The log P value is an accurate and important molecular characteristic that 
defines lipophilicity and the ability of a drug to diffuse across the lipophilic 
BBB. This is can be easily measured by dissolving the drug in n-octanol and shaking 
with equal volumes of water. The concentration of drug is then measured in both 
phases and the ratio of concentration in n-octanol/water evaluated according to  
Eq. 1 [10].
 
(1)
The estimation of drug penetrating through the BBB (log BB) is the concentra-
tion of drug in the brain divided by concentration in the blood [11].
Very lipophilic compounds also tend to be highly protein bound. For a drug to 
diffuse from the plasma (at pH 7.4) across the BBB (log BB) into the CSF, the ideal 
octanol-water partition coefficient is usually 1–10 and corresponds to a log P of 0–1 
[12]. Others recommend higher values—log P ≤ 5 [11].
In addition, when selecting a drug, the maximum concentration of drug in the 
plasma initially (Cmax) and the total drug concentration available after a single 
treatment—area under the curve (AUC), will be of assistance to predict if sufficient 
concentration of the drug is present [13].
Thus, the combination of log P, AUC and an IC10/50 values will be of assistance 
with the selection for a potentially active/useful drug for a specific individual with 
cancer (Table 1).
The above introductory information provides the general principles which gov-
ern the entry of anti-cancer cells—passively or actively, into the CNS and SNS that 
must be considered. Plus, after entering the brain, chemicals and drugs must not be 
substrates for P-glycoprotein (P-gP) transfer systems; or at least not before they can 
penetrate cancer cells and perform their anti-cancer effects.
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Compound Structure Calculated log P Calculated BB11 Actual BB12
Cis-platinum −2.83 0.09 0.05–1
Cytarabine −2.77 0.1 1
Pentostatin −2.35 0.13 0.1–0.13
Temozolomide −1.9 0.18 0.19
Cladribine −0.38 0.64 0.25
Dacarbazine −0.35 0.69 0.14
Melphalan −0.01 0.86 0.01–0.1
Busulfan 0.08 0.9 1
Topotecan 1.41 ≥1 0.42
Carmustine 1.67 ≥1 0.15–0.9
Lomustine 2.96 ≥1 >0.5
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4.  Emerging technologies for crossing the brain blood barrier designing 
new agents
The medicinal chemists and molecular pathologists are constantly designing 
new agents for neuro-oncology. The goals are always the same—continue to develop 
new integrative drug designs vs. compliment specific receptors in the BBB or on 
vessels through which cancer cells penetrate the BBB.
5. Exosomes to deliver treatments across the blood-brain barrier
Matthew Wood et al. claim that exosomes can cross the blood-brain barrier 
and deliver siRNAs, antisense oligonucleotides, chemotherapeutic agents and 
proteins specifically to cells—normal and malignant in the brain [15]. Exosomes 
are cell-derived matrix-bound encapsulated vesicles that contain drugs [15]. They 
are naturally or synthetically generated, able to cross the blood-brain barrier and 
deliver poorly solubilized drugs into the CNS and directly to brain cancer, as well as 
other diseases. Again, they must be able to pass the BBB.
6. Nanoparticles
Nanoparticle drug delivery systems contain drugs bound to nanoparticles which 
are capable of traversing the blood-brain barrier [16]. Human serum albumin (HSA) 
is most widely used vehicle to design nanoparticles. The main benefits of HSA 
nanoparticles are that they are well tolerated with minimal side effects, as well as the 
albumin functional groups can be utilized for surface modification that allows for 
specific cell uptake. Nanoparticles have been shown to transverse the blood-brain 
Compound Structure Calculated log P Calculated BB11 Actual BB12
DM-PEN 4.32 ≥1 TBD
Penclomedine 
(PEN)
4.59 ≥1 TBD
DMCHOCPEN 9.68 ≥1 TBD
Note: Not shown in Table 1 is etoposide which has a low BB value of 0.05 and it is pumped out of the brain by the 
P-gP pump [14].
Table 1. 
Calculated and structure related activities for drugs with CNS activity [5].
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barrier carrying host drugs into the brain [16]. To enhance the effectiveness of 
nanoparticles to cross the blood-brain barrier, attempts have been made to coat the 
nanoparticles with polysorbate to make them more permeable [16]. Polysorbate 80 
coated nanoparticles containing doxorubicin delivered up to 6 μg/g concentrations of 
the drug into the brain after intravenous injections of 5 mg/kg of the drug/nanopar-
ticles [16]. No detectable drug was observed when given alone or with the uncoated 
nanoparticles. This technology continues to have promise in neuro-oncology.
7. Prodrugs
CNS prodrugs are derivatized forms of active drugs that are unable to cross 
the BBB. Designing active molecules that are derivatized with lipids, amino acids, 
esters, salts, etc., can improve the former molecules’ ability to penetrate the BBB 
more efficiently [14]. In situ in the CNS the prodrugs are metabolized or degener-
ated after crossing the BBB, releasing the active form of the drug [14].
There are still major drawbacks to the use of prodrugs to treat tumors in the 
CNS. First, the prodrug may be able to pass through the BBB; however, it may be 
transported out of the CNS by the P-gP transport system without ever releasing 
the active drug. Second, the sheer size of these derivatized molecules makes it very 
difficult to pass through the BBB.
Nevertheless, this is a very promising area for new research endeavors [14].
8. Peptide masking
Similar to the prodrug concept, another method to improve drug CNS bioavail-
ability is through derivatizing drugs with peptides and amino acids that have select 
transfer pathways through the BBB and into the brain [17].
One example is through the use of cholesterol [13]. Although the brain synthe-
sizes its own cholesterol for support and metabolism, cholesteryl derivatized drugs 
behave like lipids and penetrate the BBB secondary to be lipophilic [13]. This type 
of masking works well and aids in traversing the blood-brain barrier. Also, a “target 
molecule” could be attached to the drug that helps it pass through the barrier and 
then once inside the brain released. If the drug is not transported out of the brain, 
then it is available for therapeutic use [13].
However, drawbacks to the above exist as well. Once the drug is in the brain 
there is a point where it needs to be degraded to prevent toxic changes in the brain 
tissue. Also the drug may not be transported out of the brain and could become 
toxic with increased concentration. There must always be a mechanism for the 
removal of the active form of the drug from the brain [13].
9. Receptor-mediated permeators
Drugs that increase the permeability of the BBB are described as receptor-
mediated permeators (RMP) [18]. By decreasing the restrictiveness of the BBB, it 
is much easier for a molecule to pass through the barrier. RMPs increase the perme-
ability of the blood-brain barrier temporarily by increasing the osmotic pressure in 
the blood which loosen the junctions between the endothelial cells and pericytes. By 
loosening the junctions, drugs can pass through the BBB and be available as therapy 
vs. cancer cells. These drugs must be administered in a very controlled environment 
because of the risk associated with their use [18].
7© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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First, a major concern is that the brain can be flooded with the drugs that are in 
the blood that are usually blocked by the BBB. Secondly, when the tight junctions 
loosen, the homeostasis of the brain can also be compromised, which can result in 
seizures and other dysfunctional events in the brain.
10. Microbubble-enhanced focused ultrasound
Microbubbles are small “bubbles” of mono-lipids that are able to pass through 
the BBB. One obstacle to this, however is that these microbubbles are large, which 
often prevents their diffusion through the BBB and into the brain. This can be 
counteracted by focused ultrasound. Ultrasound increases the permeability of the 
BBB by causing interference in the tight junctions in the BBB. In combination with 
ultrasound therapy, a very specific area of diffusion will develop, because micro-
bubbles can only diffuse where the ultrasound has disrupted the barrier [19, 20].
The hypothesis and usefulness of this combination is the possibility of loading a 
microbubble with an active drug to diffuse through the barrier and target a specific 
area in the brain or spine. There are several important factors that make this a viable 
solution for drug delivery. The first is that the loaded microbubble must not be 
substantially greater than the unloaded bubble. This ensures that the diffusion will 
be similar and the ultrasound disruption will be sufficient to induce diffusion. A 
second factor is that the stability of the loaded micro-bubble must be stable. This 
means that the drug is fully retained in the bubble and there is no leakage.
Lastly, it must be determined how the drug is to be released from the micro-
bubble in the CNS once it passes through the BBB. Studies have documented the 
effectiveness of employing microbubble technology to get drugs to specific sites in 
the brain in animal models and humans [19, 20].
The author hopes that the concepts discussed herein will be useful to stimulate 
research ideas that ultimately may lead to new treatments and approaches to the 
management of CNS and SNS tumors—primary and secondary.
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